Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Yum! Brands, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $530 (market cap $134.25B), while Yum! Brands, Inc. trades at $148.68 (market cap $39.50B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.4× Yum! Brands, Inc.'s market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | YUM | |
|---|---|---|
Market Cap | $134.25B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $529.65 | $168.16 |
52-Week Low | $376.62 | $138.21 |
Enterprise Value | $128.37B | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
YUM trades at $145.33, down 3.6% amid bearish technical signals and recent parasite outbreak concerns affecting Taco Bell sales. The company reported strong Q2 2026 earnings of $1.62 per share, beating estimates, with revenue growth continuing from $8.21B in 2025 to projected $8.7B in 2026. Valuation metrics show a P/E of 18.23 and P/S of 4.63, while debt reduction improved with debt-to-asset ratio declining to 143.49 in 2025.
The outlook remains mixed with analyst consensus price target of $174.60 suggesting 20% upside, but legal investigations and food safety issues pose near-term risks. Long-term growth drivers include digital expansion and portfolio optimization following Pizza Hut China sale, though execution on Taco Bell recovery is critical for sentiment improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
